Zenas BioPharma, Inc. financial data

Symbol
ZBIO on Nasdaq
Location
1000 Winter St, Suite 1200, Waltham, MA
State of incorporation
DE
Fiscal year end
December 31
Former names
Zenas BioPharma (Cayman) Ltd (to 11/15/2022)
Latest financial report
10-Q - Q3 2024 - Nov 12, 2024

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 41.8M shares
Common Stock, Shares, Outstanding 41.8M shares
Common Stock, Value, Issued 4K USD
Weighted Average Number of Shares Outstanding, Basic 7.7M shares +401%
Weighted Average Number of Shares Outstanding, Diluted 7.7M shares +305%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 33.5M USD +259%
General and Administrative Expense 7.45M USD +48.4%
Operating Income (Loss) -41M USD -215%
Nonoperating Income (Expense) 2.38M USD
Net Income (Loss) Attributable to Parent -38.6M USD -208%
Earnings Per Share, Basic -5.02 USD/shares -307%
Earnings Per Share, Diluted -5.02 USD/shares -356%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 360M USD +398%
Cash, Cash Equivalents, and Short-term Investments 387M USD
Assets, Current 394M USD
Property, Plant and Equipment, Net 146K USD
Operating Lease, Right-of-Use Asset 399K USD
Other Assets, Noncurrent 9.02M USD
Assets 403M USD
Accounts Payable, Current 15.1M USD
Employee-related Liabilities, Current 6.19M USD
Accrued Liabilities, Current 28.5M USD
Liabilities, Current 44M USD
Liabilities 44M USD
Accumulated Other Comprehensive Income (Loss), Net of Tax 54K USD
Retained Earnings (Accumulated Deficit) -335M USD
Stockholders' Equity Attributable to Parent 359M USD
Liabilities and Equity 403M USD

Popular Metrics

Label TTM Value / Value Unit Change %
Common Stock, Shares Authorized 175M shares
Common Stock, Shares, Issued 41.8M shares
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 360M USD +397%
Operating Lease, Liability 384M USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -38.7M USD -209%
Lessee, Operating Lease, Liability, to be Paid 642M USD
Operating Lease, Liability, Current 384K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 439M USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 258M USD
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 25M shares
Additional Paid in Capital 694M USD
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 2.84M USD +183%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares